Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Drug delivery to the central nervous system
Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …
development remains challenging, with high costs, long pathways to clinical use and high …
A historical review of brain drug delivery
WM Pardridge - Pharmaceutics, 2022 - mdpi.com
The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …
Zero-order drug delivery: State of the art and future prospects
Pharmaceutical drugs are an important part of the global healthcare system, with some
estimates suggesting over 50% of the world's population takes at least one medication per …
estimates suggesting over 50% of the world's population takes at least one medication per …
Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma
Among central nervous system tumors, Glioblastoma (GBM) is the most common, aggressive
and neurological destructive primary brain tumor in adults. Standard care therapy for GBM …
and neurological destructive primary brain tumor in adults. Standard care therapy for GBM …
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
Chemotherapy for brain tumours has been limited because of difficulty in achieving
adequate exposure to the tumour without systemic toxicity. We have developed a method for …
adequate exposure to the tumour without systemic toxicity. We have developed a method for …
Rationally designed drug delivery systems for the local treatment of resected glioblastoma
Glioblastoma (GBM) is a particularly aggressive brain cancer associated with high
recurrence and poor prognosis. The standard of care, surgical resection followed by …
recurrence and poor prognosis. The standard of care, surgical resection followed by …
Glioblastoma multiforme therapy and mechanisms of resistance
YP Ramirez, JL Weatherbee, RT Wheelhouse… - Pharmaceuticals, 2013 - mdpi.com
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous
population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The …
population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The …
Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases
A Chowdhury, S Kunjiappan, T Panneerselvam… - International nano …, 2017 - Springer
Degenerative diseases are results of deterioration of cells and tissues with aging either by
unhealthy lifestyle or normal senescence. The degenerative disease likely affects central …
unhealthy lifestyle or normal senescence. The degenerative disease likely affects central …
Intramedullary spinal cord tumors: a review of current and future treatment strategies
Intramedullary spinal cord tumors have low incidence rates but are associated with difficult
treatment options. The majority of patients with these tumors can be initially treated with an …
treatment options. The majority of patients with these tumors can be initially treated with an …